论文部分内容阅读
目的分析氨溴索雾化吸入结合重组人干扰素α-2a在治疗小儿毛细支气管炎方面的临床疗效。方法以我院2016年收治的部分毛细支气管炎患儿为研究对象,对其进行分组治疗,分别采用氨溴索雾化吸入和氨溴索雾化吸入结合重组人干扰素α-2a治疗,对比两组患儿的临床治疗效果。结果观察组临床总有效率为93.0%,显著优于对照组的78.0%,组间对比P<0.05;在患儿临床症状缓解、康复及转归方面,观察组患儿症状消失较快,平均住院时间显著缩短。结论采用氨溴索雾化吸入结合重组人干扰素α-2a治疗小儿毛细支气管炎可以尽快缓解患儿临床症状,缩短病程,患儿总体治疗效果佳。
Objective To analyze the clinical efficacy of inhalation of ambroxol combined with recombinant human interferon α-2a in the treatment of children with bronchiolitis. Methods The children with partial bronchiolitis treated in our hospital in 2016 were divided into groups and treated with inhalation of ambroxol and inhalation of ambroxol in combination with recombinant human interferon α-2a. Clinical efficacy of two groups of children. Results The total clinical effective rate was 93.0% in the observation group, which was significantly better than 78.0% in the control group, with a significant difference between the two groups (P <0.05). The symptom of the observation group disappeared rapidly in the clinical symptom relief, recovery and prognosis of children, Hospitalization was significantly shorter. Conclusion inhalation of ambroxol combined with recombinant human interferon α-2a treatment of children with bronchiolitis can relieve the clinical symptoms of children as soon as possible and shorten the course of the disease, the overall effect of treatment in children with good.